Should Metformin Be Our Antiglycemic Agent of Choice Post-transplantation?
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
New onset diabetes after transplantation (NODAT) is a major complication associated with solid-organ transplantation, sharing many similarities with type 2 diabetes mellitus. While metformin is recommended as the antiglycemic agent of choice in the general population, guidelines post-transplantation do not endorse metformin with equal importance and promote meglitinides as the agents of choice. Concerns with tolerability and safety of metformin in the complex polypharmacy of transplant recipients are likely causative factors for reluctant prescription among clinicians. However, such practice denies recipients a wide array of benefits attributed to metformin use in the general population. These include attenuation of abnormal glucose metabolism (diabetes treatment and prevention), weight neutrality, improvement in pathophysiological components of the metabolic syndrome (insulin resistance, subclinical inflammation, endothelial dysfunction and nonalcoholic fatty liver disease [NAFLD]), lipid-lowering properties, cardiovascular protection and antineoplastic potential. Whether such benefits translate from the general population to our high-risk recipients requires further investigation. By discussing the evidence of the risk/benefit ratio of metformin, the aim of this article is to promote the safe use of metformin as the first-line antiglycemic agent in the context of solid-organ transplantation for a host of indications that require clinical validation with appropriately designed trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“The Diabetes Audit Research in Tayside/Medicines Monitoring Unit (DARTS/MEMO) group looked at incidence of cancer in a case control study of type 2 diabetics over an 8-year analysis period (20).”
MethodBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644 · cited 1×
“Interestingly, mTOR is one of the major downstream signaling pathways regulated by LKB1/AMPK and raises an intriguing picture of inter-related signaling pathways responsible for both metabolic and cell growth control (23).”
BackgroundThe Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.5.1566 · Cited by 333
Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia
Sharif, A., Moore, R., & Baboolal, K. (2008) · Transplantation · doi:10.1097/tp.0b013e3181605ebf · Cited by 144 · cited 1×
“In addition, lifestyle modification has been shown to effectively treat NODAT and to attenuate the progression of prediabetes to NODAT in the transplant population (25).”
BackgroundSelf-citationEstablishing pragmatic estimated GFR thresholds to guide metformin prescribing
Shaw, J. S., Wilmot, R. L., & Kilpatrick, E. S. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02221.x · Cited by 90 · cited 1×
“There is no consensus as to what threshold of renal insufficiency is acceptable for continued metformin use, although recent reports suggest it is safe down to a minimum estimated glomerular filtration rate (eGFR) of 30 mL/min if not lower (28).”
Background
Cited by
Sharif, A., Hecking, M., de Vries, A. P. J., Porrini, E., Hornum, M., Rasoul-Rockenschaub, S., Berlakovich, G., Krebs, M., Kautzky-Willer, A., Schernthaner, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12850 · Cited by 532
“Metformin may be an attractive anti-hyperglycemic agent to reduce the likelihood of PTDM in high-risk individuals (49) but the benefits of metformin need to be weighed against the risks associated with metformin in the context of impaired renal function (e.”
BackgroundPost-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs583 · Cited by 120
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Metadata
- Authors
- Sharif, A.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 11
- Issue
- 7
- Pages
- 1376-1381
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1481046838
- Cited by
- 69
- References
- 10
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Should Metformin Be Our Antiglycemic Agent of Choice Post-transplantation? https://app.cochat.ai/papers/10.1111/j.1600-6143.2011.03550.x
- The paper
- Sharif, A. (2011). Should Metformin Be Our Antiglycemic Agent of Choice Post-transplantation? American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2011.03550.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.